We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




MRI and PET Used with Solid Tumor Response Evaluation Criteria to Track Treatment in Bone Metastases

By LabMedica International staff writers
Posted on 22 Sep 2014
Imaging technologies are very useful in evaluating a patient’s response to cancer treatment, and this can be done quite effectively for most tumors using solid tumor response evaluation criteria.

RECIST (Response Evaluation Criteria in Solid Tumors), however, works well for tumors located in soft tissue, but not so well for cancers that spread to the bone, such as is the case for prostate and breast cancers. More...
More effort, therefore, is needed to improve the determination of how to monitor the response of bone metastases to treatment using magnetic resonance imaging (MRI) and positron emission tomography (PET). A recent European Organization for Research and Treatment of Cancer (EORTC; Brussels, Belgium) Imaging Group review and position statement published online August 16, 2014, in the European Journal of Cancer addresses the situation.

The article published by these EORTC Imaging Group investigators emphasized the most recent developments in MRI and PET and elucidates how these techniques can be used to identify bone metastases at an early stage as well as monitor the response of these to treatments. They described the current state of the art in PET and MRI, the strengths, weaknesses and complementarity of various imaging techniques with respect to specific indications, and recommendations for choosing the most appropriate imaging technique.

Prof. Frederic Lecouvet, from the Cliniques Universitaires Saint Luc (Brussels, Belgium), and lead author of this review and position statement, said, “Assessing the response of metastases to treatment is something we do on a day to day basis, both in our oncology practice as well as for clinical trials. If the metastases occur in soft tissues, then we already have validated criteria, such as RECIST, that enable us to evaluate the response. A host of problems, however, limits our ability to measure the response to treatment of metastases found in bone. These range from the characteristics of bone metastatic disease, the structure of bone itself, to the sensitivity, specificity, and resolution of imaging methods available until now. We hope to resolve these issues, and our review is a step in the right direction.”

Techniques such as MRI and PET have the potential to detect the metastasizing of a cancer into the bone marrow at an earlier stage and also determine the extent of this spread, and the efforts of the EORTC researchers should help towards making these techniques a routine part of oncology practice.

Related Links:

European Organization for Research and Treatment of Cancer
Cliniques Universitaires Saint Luc



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Pathology

view channel
Image: The new methyl-copying PCR method preserves DNA methylation patterns during amplification (Photo courtesy of Syndex Bio)

Novel mcPCR Technology to Transform Testing of Clinical Samples

DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.